260 related articles for article (PubMed ID: 15239393)
21. Imatinib for systemic mast-cell disease.
Pardanani A; Elliott M; Reeder T; Li CY; Baxter EJ; Cross NC; Tefferi A
Lancet; 2003 Aug; 362(9383):535-6. PubMed ID: 12932387
[TBL] [Abstract][Full Text] [Related]
22. The results of imatinib therapy for patients with primary eosinophilic disorders.
Helbig G; Stella-Holowiecka B; Grosicki S; Bober G; Krawczyk M; Wojnar J; Reiter A; Hochhaus A; Holowiecki J
Eur J Haematol; 2006 Jun; 76(6):535-6. PubMed ID: 16608506
[No Abstract] [Full Text] [Related]
23. [Myeloproliferative hypereosinophilic syndrome revealed by bipolar mucosal ulcerations].
Isvy-Joubert A; Hickman G; Flageul B; Battistella M; Bagot M; Galicier L; Petit A
Ann Dermatol Venereol; 2012 Oct; 139(10):636-40. PubMed ID: 23122377
[TBL] [Abstract][Full Text] [Related]
24. Myeloid neoplasm with prominent eosinophilia and PDGFRA rearrangement treated with imatinib mesylate.
Rathe M; Kristensen TK; Møller MB; Carlsen NL
Pediatr Blood Cancer; 2010 Oct; 55(4):730-2. PubMed ID: 20589620
[TBL] [Abstract][Full Text] [Related]
25. p53-Binding protein 1 is fused to the platelet-derived growth factor receptor beta in a patient with a t(5;15)(q33;q22) and an imatinib-responsive eosinophilic myeloproliferative disorder.
Grand FH; Burgstaller S; Kühr T; Baxter EJ; Webersinke G; Thaler J; Chase AJ; Cross NC
Cancer Res; 2004 Oct; 64(20):7216-9. PubMed ID: 15492236
[TBL] [Abstract][Full Text] [Related]
26. A critical appraisal of conventional and investigational drug therapy in patients with hypereosinophilic syndrome and clonal eosinophilia.
Kalac M; Quintás-Cardama A; Vrhovac R; Kantarjian H; Verstovsek S
Cancer; 2007 Sep; 110(5):955-64. PubMed ID: 17654661
[TBL] [Abstract][Full Text] [Related]
27. A novel form of mastocytosis associated with a transmembrane c-kit mutation and response to imatinib.
Akin C; Fumo G; Yavuz AS; Lipsky PE; Neckers L; Metcalfe DD
Blood; 2004 Apr; 103(8):3222-5. PubMed ID: 15070706
[TBL] [Abstract][Full Text] [Related]
28. World Health Organization-defined eosinophilic disorders: 2011 update on diagnosis, risk stratification, and management.
Gotlib J
Am J Hematol; 2011 Aug; 86(8):677-88. PubMed ID: 21761433
[TBL] [Abstract][Full Text] [Related]
29. A case of myeloid neoplasm associated with eosinophilia and KIAA1509-PDGFRβ responsive to combination treatment with imatinib mesylate and prednisolone.
Wang JR; Yen CC; Gau JP; Hsiao LT; Liu CY; Pai JT; Tzeng CH; Teng HW
J Clin Pharm Ther; 2010 Dec; 35(6):733-6. PubMed ID: 21054467
[TBL] [Abstract][Full Text] [Related]
30. Treatment options for chronic myeloid leukemia: imatinib versus interferon versus allogeneic transplant.
Angstreich GR; Smith BD; Jones RJ
Curr Opin Oncol; 2004 Mar; 16(2):95-9. PubMed ID: 15075898
[TBL] [Abstract][Full Text] [Related]
31. [Sustained hematologic response in chronic eosinophilic leukemia with low dose imatinib. Report of one case].
Torres C D; Chandía M
Rev Med Chil; 2014 Apr; 142(4):516-20. PubMed ID: 25117044
[TBL] [Abstract][Full Text] [Related]
32. Response to imatinib mesylate in a patient with idiopathic hypereosinophilic syndrome associated with cyclic eosinophil oscillations.
Imashuku S; Kakazu N; Ueda I; Morimoto A; Harada H; Teramura T; Tamura S; Fukushima-Nakase Y; Kuroda H
Int J Hematol; 2005 May; 81(4):310-4. PubMed ID: 15914361
[TBL] [Abstract][Full Text] [Related]
33. Clinical, genetic, and therapeutic insights into systemic mast cell disease.
Tefferi A; Pardanani A
Curr Opin Hematol; 2004 Jan; 11(1):58-64. PubMed ID: 14676628
[TBL] [Abstract][Full Text] [Related]
34. [Systemic mastocytosis without the typical mutation of codon 816 successfully treated with imatinib].
Hirayama Y; Konuma Y; Kohda K; Ando M; Obata M; Ueno Y; Sasagawa Y; Wada Y; Shirao S
Nihon Naika Gakkai Zasshi; 2008 Oct; 97(10):2542-5. PubMed ID: 19051746
[No Abstract] [Full Text] [Related]
35. Successful treatment of KIT D816V-positive, imatinib-resistant systemic mastocytosis with interferon-alpha.
Yoshida C; Takeuchi M; Tsuchiyama J; Sadahira Y
Intern Med; 2009; 48(22):1973-8. PubMed ID: 19915299
[TBL] [Abstract][Full Text] [Related]
36. Cytoreductive therapy in 108 adults with systemic mastocytosis: Outcome analysis and response prediction during treatment with interferon-alpha, hydroxyurea, imatinib mesylate or 2-chlorodeoxyadenosine.
Lim KH; Pardanani A; Butterfield JH; Li CY; Tefferi A
Am J Hematol; 2009 Dec; 84(12):790-4. PubMed ID: 19890907
[TBL] [Abstract][Full Text] [Related]
37. A diagnostically difficult case of chronic myeloid neoplasm with eosinophilia and abnormalities of PDGFRA effectively treated with imatinib in accelerated phase: case report.
Rodzaj M; Gałazka K; Majewski M; Zduńczyk A
Pol Arch Med Wewn; 2009 Dec; 119(12):838-41. PubMed ID: 20010473
[TBL] [Abstract][Full Text] [Related]
38. [Clonal eosinophilia revealed by recurrent Staphylococcus aureus infection].
Vandenbos F; Figueredo M; Dumon-Gubeno MC; Nicolle I; Tarhini A; Medioni LD; Naman H; Mouroux J
Rev Pneumol Clin; 2011 Jun; 67(3):167-9. PubMed ID: 21665081
[TBL] [Abstract][Full Text] [Related]
39. Beyond chronic myelogenous leukemia: potential role for imatinib in Philadelphia-negative myeloproliferative disorders.
Cortes J; Kantarjian H
Cancer; 2004 May; 100(10):2064-78. PubMed ID: 15139047
[TBL] [Abstract][Full Text] [Related]
40. Treatment of systemic mast cell disease: beyond interferon.
Tefferi A
Leuk Res; 2004 Mar; 28(3):223-4. PubMed ID: 14687615
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
